immunogenicity of pneumococcal vaccine in children with systemic lupus erythematosus
- Conditions
- systemic lupus erythematosus (SLE).Systemic lupus erythematosus
- Registration Number
- IRCT138811293361N1
- Lead Sponsor
- Shiraz University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
inclusion criteria of case group: 2-18 years old; SLE disease
exclusion criteria of case group: fever; recent immunization; history of previous pneumococcal vaccination; history of hypersensitivity reaction to vaccination; platelet level less than 50,000 ; mixed connective tissue disorders; IVIG injection in last 3 months.
inclusion criteria of control group: 2-18 years old; mild asthma
exclusion criteria of control group: fever; recent immunization; history of previous pneumococcal vaccination; history of hypersensitivity reaction to vaccination; platelet level less than 50,000 ; mixed connective tissue disorders; IVIG injection in last 3 months; patients with persistent or severe asthma; patients with history of immunosuppressive therapy or PO corticosteroid consumption; patient with history of other immunodeficiency disorders
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Speific anti-pneumococcal antibody. Timepoint: before vaccination and 3 weeks after intervention. Method of measurement: using enzyme linked immunoassay kit specific for pneumococcal vaccine (ELISA).;Lupus activity. Timepoint: before vaccination and 3 weeks after intervention. Method of measurement: according to SLE disease activity index (SLEDAI).
- Secondary Outcome Measures
Name Time Method SLE activity. Timepoint: before vaccination and 3 weeks after intervention. Method of measurement: according to SLE disease activity index.